Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Connor A Ott

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Trends in Cancer|August 5, 2023
Targeting TEAD-ious resistanceConnor A Ott, Andrew E Aplin
Nature Communications|March 9, 2022
Differential recognition of canonical NF-κB dimers by Importin α3Tyler J Florio, Ravi K Lokareddy, Daniel P Yeggoni, et al.
Molecular Cancer Therapeutics|June 21, 2023
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant MelanomaMcKenna Q Glasheen, Signe Caksa, Amelia G Young, et al.
Molecular Cancer Research : MCR|October 17, 2023
SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell DeathSheera R Rosenbaum, Signe Caksa, Casey D Stefanski, et al.
Nature Communications|November 10, 2021
Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B-related neurodevelopmental disordersLuca Pagliaroli, Patrizia Porazzi, Alyxandra T Curtis, et al.
Nature Communications|November 5, 2025
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma modelsConnor A Ott, Timothy J Purwin, Pan-Yu Chen, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Trends in Cancer|August 5, 2023
Targeting TEAD-ious resistanceConnor A Ott, Andrew E Aplin
Nature Communications|March 9, 2022
Differential recognition of canonical NF-κB dimers by Importin α3Tyler J Florio, Ravi K Lokareddy, Daniel P Yeggoni, et al.
Molecular Cancer Therapeutics|June 21, 2023
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant MelanomaMcKenna Q Glasheen, Signe Caksa, Amelia G Young, et al.
Molecular Cancer Research : MCR|October 17, 2023
SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell DeathSheera R Rosenbaum, Signe Caksa, Casey D Stefanski, et al.
Nature Communications|November 10, 2021
Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B-related neurodevelopmental disordersLuca Pagliaroli, Patrizia Porazzi, Alyxandra T Curtis, et al.
Nature Communications|November 5, 2025
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma modelsConnor A Ott, Timothy J Purwin, Pan-Yu Chen, et al.
Pageof 1